This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Indicated for long term female contraception.  Click here for Sayana®-Press (medroxyprogesterone acetate) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

About Sayana®-Press

Sayana-Press delivers precise dosing via a simple, single dose device and has proven efficacy.1,2,3

1. Sayana-Press: a LARC with choices

  • Simple device – uses innovative Uniject™ Technology.1
  • Easy-to-follow injection instructions – 23 gauge needle attached for subcutaneous injection, no specialised training for HCPs.1,2
  • Administration options – HCP administration in clinic or self-administration by women, when considered appropriate by HCP.2*

Video Guide

Watch this guide on self-administrating Sayana-Press.

2. Efficacy

99% effective in preventing pregnancy if used according to the product recommendations of every 13 weeks (+/-7 days).4
Two open-label, multi-national, multi-centre, Phase III, 1-year trials were undertaken in order to assess the efficacy and safety of DMPA subcutaneous (DMPA-SC injection).4

Americas Trial:

Conducted at 36 sites and involved 722 women in the ITT (Intent-To-Treat) population.

European/Asian Trial:

Conducted at 64 sites (including UK sites) and involved 1065 women in the ITT populations

  • A substantial number of overweight or obese women (>26%) took part in the trials. Efficacy was unaffected by body weight and so no dosage adjustments for body weight are required.4
  • No pregnancies were observed at 1-year across 16,023 woman-cycles of exposure with DMPA-SC.4
  • DMPA-SC was found to be an effective and generally well-tolerated method of contraception with comparable efficacy to DMPA-IM.4

3. Precise dosing

Sayana-Press delivers an immediate 13 weeks of contraception.2††

*Self-administration should be first performed under the supervision of an HCP following training of the woman in proper injection technique and schedule of administration.

Providing the first injection is given during the first five days of a normal menstrual cycle and subsequent injections are given no later than thirteen weeks and seven days after the previous injection.

††Sayana-Press does not protect against sexually transmitted infections (STIs)

To read the full special warnings and precautions for use for Sayana-Press and see a full list of adverse events, refer to the Summary of Product Characteristics. The benefits of contraceptive options and their risks must be evaluated individually for each woman. If any of the conditions/risk factors mentioned is present, the benefits of Sayana-Press use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether Sayana-Press use should be discontinued.

Managing Expectations

What can women expect from Sayana-Press?

Learn More


References:
  1. PATH website: Uniject. Last accessed December 2020.
  2. Sayana-Press Summary of Product Characteristics. Available at:https://www.medicines.org.uk/emc/medicine/27798/SPC/SAYANA+PRESS+104+mg+0.65+ml+suspension+for+injection/ Last accessed December 2020.
  3. Depot-medroxyprogesterone acetate (DMPA-SC) Sayana Press WHO EML Application December 2016. Available at: https://www.who.int/selection_medicines/committees/expert/21/applications/s18_medroxyprogesterone_acetate_form.pdf Last accessed February 2021.
  4. Jain J, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004;70:269-275.
PP-SAY-GBR-0187. February 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No